Moleculin Biotech CS MBRX

$7.87 -0.19 (-2.36%)

Valuation

Market cap
8,280,000
Revenue TTM
$0
Net income TTM
$-33,560,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
9,800
Avg volume
47,283
Day's range
$7.71 – $8.10
Shares out
1,027,000
Stochastic %K
13%
Beta
2.11
Analysts
Strong Buy
Price target
$240.00

Price

Company profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP...

Show more

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Industry
Biotechnology
Sector
Healthcare
Phone
713 300 5160
Website
https://moleculin.com
Address
5300 Memorial Drive, Suite 950, Houston, United States

Latest news

Stocktwits

Traveladvisor Nov 13, 10:28 PM
$MBRX – Great news for Moleculin! Nasdaq has granted the company a conditional extension until March 15, 2027. This is an important development, especially considering that the full results from the first 90 patients in the MIRACLE trial are expected in Q1 2027. The initial 45 patients have already shown very promising results for Annamycin in the treatment of acute myeloid leukemia. Meanwhile, the company continues to strengthen its international patent portfolio and will present clinical data at the ASH conference in December. I believe the market is significantly undervaluing Annamycin’s potential. With such a low market capitalization, strong clinical results could completely change the company’s valuation and attract interest from potential pharmaceutical partners.
1 replies
Traveladvisor Nov 13, 10:11 PM
$MBRX
0 replies
d_risk Nov 13, 9:49 PM
$MBRX - Moleculin Biotech, Inc. - 10Q - Updated Risk Factors Moleculin says Nasdaq granted a conditional listing exception through March 15, 2027. Failure to meet the conditions would subject its shares to immediate delisting. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/MBRX?filing=GHKwv1i3B2ymI845AHgMU
0 replies
ReversalRuler Nov 13, 7:13 PM
If you’ve ever wanted to catch a short squeeze early instead of watching it rip after the fact, this group is built for that. Sharing momentum, setups, and what we’re watching as it develops, not when it’s already gone. Click link and join for Free ⭐ $POM $EHGO $REVB $MBRX ..
0 replies
Merlintrader Nov 13, 1:54 PM
$MBRX Moleculin, Nov 12: granted an Australian patent on the preparation of preliposomal Annamycin lyophilizate, held with the University of Texas. Annamycin data were also accepted for ASH 2026. Not investment advice. More on this, plus catalysts and cash, in the $MBRX stock hub: https://www.merlintrader.com/moleculin-biotech-stock-hub/
0 replies
BioTuesdays Nov 12, 8:27 PM
$MBRX has announced an Australian patent covering the preparation of preliposomal Annamycin lyophilizate, strengthening its intellectual property protection for the formulation technology. https://biotuesdays.com/2026/11/12/moleculin-secures-australian-patent-for-annamycin-formulation-technology/
0 replies
ReversalRuler Nov 12, 6:30 PM
$PURR $DKI $POM $MBRX \
0 replies
Traveladvisor Nov 12, 2:52 PM
$MBRX Annamycin has been accepted for presentation at the 2026 Annual Meeting of the American Society of Hematology (ASH), which will take place from December 12–15, 2026, in New Orleans, Louisiana. The abstract presents the results of the first pre-specified interim analysis of the company’s pivotal Phase 2/3 MB-108 (MIRACLE) trial, evaluating Annamycin in combination with cytarabine (Ara-C) in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).
0 replies